Corporate Governance
ISR Immune System Regulation Holding AB (publ)
Org.nr. 559026-7828
BOLAGSORDNING (swe)
§ 1
Bolagets företagsnamn är ISR Immune System Regulation Holding AB (publ).
§ 2
Styrelsen skall ha sitt säte i Stockholms kommun, Stockholms län.
§ 3
Bolaget skall, direkt eller genom hel- eller delägda dotterbolag, bedriva forskning och utveckling inom det medicinska området, marknadsföra och försälja medicinska tjänster och produkter samt bedriva annan därmed förenlig verksamhet.
§ 4
Aktiekapitalet skall utgöra lägst 3 000 000 och högst 12 000 000 kronor.
§ 5
Antalet aktier skall vara lägst 60 000 000 och högst 240 000 000.
§ 6
Styrelsen skall bestå av 3 – 8 ledamöter utan suppleanter.
§ 7
Bolaget skall ha en till två revisorer med eller utan revisorssuppleanter eller ett registrerat revisionsbolag.
§ 8
Kallelse till bolagsstämma ska ske genom annonsering i Post- och Inrikes Tidningar och genom att kallelsen hålls tillgänglig på bolagets webbplats. Att kallelse har skett ska annonseras i Svenska Dagbladet.
Aktieägare som vill delta i bolagsstämma ska göra anmälan härom till bolaget senast den dag som anges i kallelsen till bolagsstämman. Sistnämnda dag får inte vara söndag, annan allmän helgdag, lördag, midsommarafton, julafton eller nyårsafton och inte infalla tidigare än femte vardagen före bolagsstämman.
Aktieägare får vid bolagsstämma medföra ett eller två biträden, dock endast om aktieägaren har anmält detta enligt föregående stycke.
§ 9
På årsstämma skall följande ärenden förekomma till behandling:
Val av ordförande vid stämman.
Upprättande och godkännande av röstlängd.
Val av en eller två justeringsmän.
Prövning av om stämman blivit behörigen sammankallad.
Godkännande av dagordning.
Framläggande av årsredovisning och revisionsberättelse samt i förekommande fall koncernredovisning och koncernrevisionsberättelse.
Beslut om:
a) fastställande av resultaträkning och balansräkning samt i förekommande fall koncernresultaträkning och koncernbalansräkning,
b) dispositioner beträffande bolagets vinst eller förlust enligt den fastställda balansräkningen,
c) ansvarsfrihet åt styrelseledamöterna och verkställande direktören.
Fastställande av arvoden till styrelsen och revisorerna.
Val av styrelseledamöter samt av revisorer.
Annat ärende som ankommer på årsstämman enligt aktiebolagslagen (2005:551) eller bolagsordningen.
§ 10
Bolagsstämma kan, förutom där styrelsen har sitt säte, hållas i Solna.
§ 11
Kalenderåret skall vara bolagets räkenskapsår.
§ 12
Bolagets aktier skall vara registrerade i ett avstämningsregister enligt lagen (1998:1479) om värdepapperscentraler och kontoföring av finansiella instrument.
Share holders of ISR Immune System Regulation Holding AB are summoned to an Extraordinary general meeting on April 23rd, 2024. The meeting begins at 16:30 local time at Nanna Svartz väg 2, 171 65 Solna, Sweden. Registration begins at 16:00. Please see the summon attached (swedish PDF).
Extraordinary general meeting April 23rd 2024 (swe) (updated) (PDF) Warrant program 2024-2027, Board members (swe) (PDF) Warrant program 2024-2027, Management and Key figures (swe) (PDF) Extraordinary General Meeting Minutes, April 2024 (swe) (PDF)Share holders of ISR Immune System Regulation Holding AB are summoned to an Extraordinary general meeting on March 18th, 2024. The meeting begins at 11 o'clock local time at the ISR office at Retzius Väg 11, 171 Solna, Sweden. Registration begins at 10 o'clock. Please see the summon attached (swedish PDF).
Extraordinary general meeting summon (swe) (PDF)Uppdatering 2024-02-23:
Den extra bolagsstämman i ISRAB som kallades till den 27 februari kl 16:00 kommer att ställas in med hänsyn till att ledtiden för publicering gjorde att kallelsetiden blev för kort och inte kunde publiceras inom ramen för bolagsordningen. Styrelsen arbetar nu med en ny kallelse som inom kort kommer att publiceras.Styrelsen ISR
KALLELSE TILL FORTSATT STÄMMA I ISR IMMUNE SYSTEM REGULATION HOLDING AB (PUBL)
Aktieägarna i ISR Immune System Regulation Holding AB (publ), org.nr 559026–7828, kallas härmed till Extra Bolagsstämma den 27 februari 2024 klockan 16.00 i bolagets lokaler, Retzius väg 11, 171 65 Solna. Inregistrering till stämman börjar klockan 15.00.
Rätt att delta och anmälan Rätt att delta i årsstämman har den som
- - dels är införd i den av Euroclear Sweden AB förda aktieboken den 20 februari 2024,
- - dels anmält sig till bolaget senast den 25 februari 2024 under adress ISR Immune System Regulation Holding AB (publ), Att: Årsstämma, Retzius Väg 11, 171 65 Solna, alternativt via e‐post till [email protected]. I anmälan ska uppges namn eller företagsnamn, personnummer eller organisationsnummer, adress, telefonnummer, aktieinnehav och eventuella biträden (högst t
- - Stämmans öppnande
- - Val av ordförande vid stämman
- - Upprättande och godkännande av röstlängd
- - Val av minst en justeringsman
- - Godkännande av dagordning
- - Genomgång av finansiella situation
- - Val av revisor
- - Val av kompletterande ledamöter i styrelsen
- - Övriga frågor
Förvaltarregistrerade aktier
Aktieägare som låtit förvaltarregistrera sina aktier måste, för att få delta i stämman och utöva sin rösträtt, tillfälligt inregistrera aktierna i eget namn i aktieboken hos Euroclear (s.k. rösträttsregistrering). Framställningen av bolagsstämmoaktieboken per avstämningsdagen den 20 februari 2024 kommer att beakta rösträttsregistreringar. Det innebär att aktieägaren i god tid före denna dag måste begära att förvaltaren genomför sådan rösträttsregistrering.
Ombud m.m.
Aktieägare som företräds av ombud ska utfärda fullmakt för sådant ombud. Om fullmakten utfärdats av juridisk person ska bestyrkt kopia av registreringsbevis för den juridiska personen, som utvisar behörighet att utfärda fullmakten, bifogas. Fullmakten i original samt eventuellt registreringsbevis bör i god tid före stämman insändas till ISR Immune System Regulation Holding AB (publ), Att: Årsstämma, Retzius Väg 11, 171 65 Solna. Fullmakt får inte vara äldre än ett år om det inte anges längre giltighetstid i fullmakten (högst fem år). Fullmaktsformulär finns tillgängligt på bolagets webbplats, www.israb.se.
Förslag till dagordning
Aktieägarnas frågerätt
Aktieägarna erinras om rätten att vid stämman begära upplysningar från styrelsen och verkställande direktören i enlighet med 7 kap 32 § aktiebolagslagen.
Behandling av personuppgifter
För information om hur dina personuppgifter behandlas hänvisas till den integritetspolicy som finns tillgänglig på Euroclears hemsida: www.euroclear.com/dam/ESw/Legal/Integritetspolicy‐bolagsstammor‐svenska.pdf. ISR Immune System Regulation Holding AB (publ) har organisationsnummer 559026–7828 och säte i Stockholm.
Stockholm 13 februari 2024
ISR Immune System Regulation Holding AB (publ)
Styrelsen
The Continued Annual General Meeting of ISR Immune System Regulation Holding AB (publ) will be held on August 25, 2023. See the notice for further information.
ISR Holding 2023 Summon – Continued annual general meeting (swe) (PDF) ISR Holding 2022 Annual report (swe) (PDF) ISR Holding 2023 Proxy form – Continued annual general meeting (swe) (PDF) Letter to the shareholders, August 2023 (swe) (PDF) Annual General Meeting Minutes, August 2023 (swe) (PDF)The Annual General Meeting of ISR Immune System Regulation Holding AB (publ) will be held on June 24, 2024. See the notice for further information.
ISR Holding 2024 Summon (swe) (PDF) Annual general meeting record 2024 (swe) (PDF)The Annual General Meeting of ISR Immune System Regulation Holding AB (publ) will be held on June 30, 2023. See the notice for further information.
ISR Holding 2023 Summon (swe) (PDF) ISR Holding 2023 Proxy form (swe) (PDF) The nomination committee's proposal to the board 2023 (swe) (PDF) ISR Holding 2022 Annual report (swe) (PDF) ISR Holding 2022 Auditors report (swe) (PDF) Extraordinary general meeting record 2023 (swe) (PDF) Annual General Meeting record 2023, incl. electoral roll (swe) (PDF)The Annual General Meeting of ISR Immune System Regulation Holding AB (publ) will be held on June 2, 2022. See the notice for further information.
ISR Holding 2022 Summon (swe) (PDF) ISR Holding 2022 Proxy form (swe) (PDF) ISR Holding 2021 Annual report (swe) (PDF) ISR Holding 2021 Annual report (eng) (PDF) The Board proposes authorization for the issue of new shares (swe) (PDF) The nominating committee's proposal for stock option rights (swe) (PDF) Appendix A - Terms for stock option rights (Board and key personnel) (swe) (PDF) Appendix A - Terms for stock option rights (Board) (swe) (PDF) The Board's proposal for stock option rights (Board and key personnel) (swe) (PDF) Annual general meeting record 2022, excl. electoral roll (swe) (PDF)The Annual General Meeting of ISR Immune System Regulation Holding AB (publ) will be held on June 3, 2021 by postal ballot. See the notice for further information.
ISR Holding 2021 Summon (swe) (PDF) ISR Holding 2021 Proxy form (swe) (PDF) ISR Holding 2021 Postal voting form (swe) (PDF) ISR Holding 2021 Proposal for emission authorization (swe) (PDF) ISR Holding 2021 The Nomination Committee's proposal for Nomination Committee instructions (swe) (PDF) ISR Holding 2021 Proposal to amend the Articles of Association (swe) (PDF) ISR Holding 2021 Appendix Articles of Association (swe) (PDF) ISR Holding 2021 Draft audit report (swe) (PDF)The Annual General Meeting of ISR Immune System Regulation Holding AB (publ) was held on April 27, 2019, at 10:00 at Scandic Continental, Vasagatan 22, 111 20 Stockholm.
ISR Holding 2020 Summon (swe) (PDF) ISR Holding 2020 Proxy form (swe) (PDF) ISR Holding 2020 Minutes of the Annual General Meeting (swe) (PDF)The Annual General Meeting of ISR Immune System Regulation Holding AB (publ) was held on May 9, 2019, at 14:00 at Günther & Wikberg Fondkommission, Kungsgatan 3, 111 43 Stockholm.
ISR Holding 2019 Summon (swe) (PDF) ISR Holding 2019 Proxy form (swe) (PDF) ISR Holding 2019 Minutes of the Annual General Meeting (swe) (PDF)The Annual General Meeting of ISR Immune System Regulation Holding AB (publ) was held on May 23, 2018, at 14:00 in Stockholm.
ISR Holding 2018 Minutes of the Annual General Meeting (swe) (PDF)The Annual General Meeting of ISR Immune System Regulation Holding AB (publ) was held on Thursday, February 9, 2017, at 14.00 at Advokatfirman Nerpin's office, Birger Jarlsgatan 2, 3rd floor in Stockholm.
ISR Holding 2017 Minutes of the Annual General Meeting (swe) (PDF)
2017 – Now HiQ Bygg AB – CEO/Founder - Management consultant mainly in the construction and real estate industry.
2015 – 2017 WSP Management - Management consultant in the construction industry.
2011 – 2014 Ericsson AB - Logistics and NPI project manager for telecom equipment.
2005 – 2015 HiQ Bygg AB – CEO/Founder - Project Manager in the construction industry.
1998 – 2007 Ericsson AB - Production, development (RND), sourcing and project management.
1997 – 1998 ABB High Voltage Cables AB - Production and design for high voltage cables.
ISR: Shareholder since 2022. Invested in the company when he saw the opportunity to change the vaccination industry with a new platform that does not require injection, cold chains and healthcare staff.
2023 – Now Benteler Automotive Skultuna AB, CEO with 185 subordinates.
2019 – 2023 Benteler, Operation Manager in Eastern Europe with about 700 subordinates.
2017 – 2019 Benteler Automotive Skultuna AB - Manufacturing Manager with 110 reports.
2014 – 2017 Benteler Automotive Skultuna AB - Supply Chain Manger.
Benteler Skultuna has customers in Europe, Asia and North America and delivers directly
to major OEMs such as Volvo, BMW, Audi, Porsche and Daimler.
A total of 14 years of experience in the Automotive industry, both in Sweden and in Europe. Hence a large network in automotive both nationally and internationally.
ISR: Has been invested in ISR since the beginning of Covid and sees huge potential in ISR’s research.
2023 – 2024 Debe Drill Group, CEO
2023 – 2023 Debe Flow Group, Research And Development Manager
2016 – 2023 Megatec Information Technology AB, CEO (partner 2019-2021)
2016 – 2016 Speed Services AB, Sales and Marketing Manager
2010 – 2016 NordicFleet Management, Consultant in Fleet Management
ISR: Has been invested in ISR since the beginning of Covid and sees huge potential in ISR’s research.
2022 – Now QBR Systems AB, CEO/Founder. New container system for the shipping industry.
2016 – 2022 B Kubik Resurs AB, CEO/Founder of the Staffing Industry (Construction) Group.
At its peak, the Group had about 125 employees, with a piking turnover of about SEK 100 million.
The group was knocked out by the Covid-19 pandemic.
2008 – 2016 Scandinavian Screen Solutions AB, CEO/Founder
Import/purchase and sale of LED screens from China.
2002 – 2008 MCE Bild & Ljud AB (Radio-TV Shop), CEO/Founder. Turnover approx. 10 million SEK.
2022 – Now ISR-SMAFF Cooperative Society, Chairman
Approximately 300 members who jointly represent approximately 14% of the shares in ISR (approximately 11,500,000 shares).
ISR: With frequent travel to China during 2008 – 2016, interest in Hepatitis B was aroused.
ISR's HVB study was what made me invest in ISR as a company in 2019.
-1655364918.jpg)
Ola Winqvist has more than 30 years of experience in immunological research and is a professor of cellular immunotherapy and chief physician in clinical immunology. He was previously chairman of the Swedish Immunology Association and is now chairman of the Swedish Medical Association's research delegation. The Cancer Foundation and the Swedish Research Council have continuously supported Olas research since 1999. He has also received various competitive grants from the European Union and the Swedish Agency for Innovation Systems for the Development of Immunological Therapy. Ola Winqvist is a specialist and Chief Physician in Clinical Immunology and has a doctorate from Uppsala University in Sweden. He has more than 30 patents and has started several spin-off companies. In 2013, his research was awarded the Athena Prize.
Other assignments: Chairman of the Delegation for research at the Swedish Medical Association and ImmunoWise AB. Board member of, among others, TLA Targeted Immunotherapies AB.
-1655364969.jpg)
2021 – 2024 ISR Holding AB (publ), CFO
2014 – 2023 Implement Consulting Group, Partner
2001 – 2014 Capgemini, Miscellaneous management positions
1994 – 2001 Ernst & Young, Auditor and Consultant
1990 – 1994 Swedish Army, Reserve Officer
-1655365151.jpg)
Dr. Rohmann received his MD from the University of Mainz, Germany, and his PhD from the Erasmus University of Rotterdam, Netherlands. He is significantly experienced in M&A and the pharmacutical industry, and spend 10 years at Merck Serono.
Dr Rohmann was also a Managing Partner of Nextech Venture in Switzerland, as well as responsible as Venture Capital Fund Manager for a Novartis Pharma AG. From 2010 to 2014 he was General Manager Europe for Burill & co, a Helthcare Venture Fund with more than $1.5 billion (USD) under management.
-1655365202.jpg)
Jacob Harker has a BSc from University of Swansea, Great Britain. He has significant experience in the development of inhaled medicines with more than 20 years of industrial experience from Pfizer, AstraZeneca, PowderJect and Circassia. He also has extensive experience in leading CMC programmes, with focus on formulating and developing medicines by the means of particle technology for delivery via lungs, nasally and through the skin.
-1655365248.jpg)
Nigel Goodman has a BSc in Pharmacology, Physiology and Microbiology from the University of Liverpool as well as a MBA from Manchester. He has a significant background in the development of innovative medicines with more than 35 years of industrial experience, from Hoffmann-La Roche in Great Britain and globally, and an American CRO. Since founding Gaea in 1994, and as the CEO of GaeaOÜ, a CRO based in Estonia, he has obtained extensive experience of the design and realization of global clinical studies for biotechnology companies.
CEO Singapore Ltd. An international businessman that is the advisor to the government of Moldavia. vice president of international affair TLA and CarryGenes
Accountant
PWC
Chartered Accountant: Magnus Lagerberg
[email protected]
010-212 59 55
Latest press releases
Press release 2024-07-29
PM ISR 2024-07-27
Press release 2023-08-28
ISR’s, SARS-CoV-2 dry powder nasal - vaccine booster candidate, ISR52, demonstrates superior immune response, in mouse model challenge studies compared to subcutaneous injection of this vaccine.
Press release 2023-08-25
ISR Immune System Regulation Holding AB (Publ.) styrelseledamot Anders Olsson Fogelberg lämnar sitt uppdrag av hälsoskäl.
Subscribe to news and pressreleases
Privacy Notice for Email marketing
What personal data about you do we collect and why?
We have the capability to collect and hold your personal data including first and last name, job title, department, influence level, company, primary address (country, state, city, post/zip code), email address(s), phone/mobile/fax/home number(s), secondary address, gender, birthday, name of your assistant, assistant contact details in our ISR systems. We utilize this data for the purposes of relationship management (contact and administration), as well as marketing communications.
Who may have access to your personal data and why?
Employee within ISR Group with authorized access control rights as set by ISR access management can access your data for the purposes described in this privacy notice. These may include, but are not limited to, ISR employees in sales, marketing, finance and customer service functions.
How long will your personal data be stored, by whom and where?
Your personal data will be retained in ISR systems by the companies belonging to ISR Group and its third-party service providers for the duration of your relationship with ISR, or until such time when you expressly request for your data to be deleted.
What rights do you have in respect to your personal data?
If you wish to know what data we store and where, how we have used your data or to exercise your rights to request the correction or deletion of your data from ISR systems, or withdraw consent entirely, please contact [email protected]